User
Notification
Business Standard

Don’t miss the latest developments in business and finance.

Epilepsy Study

Zydus Lifesciences on Friday said it has launched generic epilepsy treatment medication in the US market. Zydus Pharmaceuticals (USA) Inc, a unit of the company, has launched Topiramate extended-release capsules in the American market. The company had earlier received final approval from the US Food and Drug Administration (USFDA) to market the product in strengths of USP 25 mg, 50 mg, and 100 mg, Zydus Lifesciences said in a statement. Zydus is the first company to receive final approval and launch the medication in the above mentioned strengths, it added. Topiramate extended-release capsules are indicated for epilepsy: initial monotherapy in patients who are six years of age and older with partial onset or primary generalized tonic-clonic seizures. It is also indicated for prophylaxis of migraine in patients 12 years of age and older. As per IQVIA data, Topiramate extended-release capsule had annual sales of USD 488 million in the US.

Updated On: 06 Jan 2023 | 5:39 PM IST
Bs_logoZydus Lifesciences launches generic anti-epilepsy drug in US market

Zydus Cadila on Monday said it has received tentative approval from the US health regulator to market epilepsy treatment drug Brivaracetam tablets.

Updated On: 14 Jun 2021 | 11:57 AM IST
Bs_logoZydus Cadila gets USFDA tentative nod for epilepsy treatment drug

The largest-ever neuroimaging study of people with epilepsy shows that epilepsy involves more widespread physical differences than previously assumed

Updated On: 22 Jan 2018 | 11:25 AM IST
Bs_logoEpilepsy associated with brain volume, thickness differences: Study